UNITED KINGDOM – AstraZeneca and Honeywell have collaborated to develop next-generation respiratory inhalers that will use the propellant HFO-1234ze, which has up to 99.9% less Global Warming Potential (GWP) than propellants currently used in respiratory medicines.

The announcement coincides with the release of the Company’s annual Sustainability Report and demonstrates progress on its flagship sustainability program, Ambition Zero Carbon.

According to a joint statement by the two companies, the products will be used to treat asthma and chronic obstructive pulmonary disease.

Asthma affects 339 million children and adults, and chronic obstructive pulmonary disease affects 384 million people.

Many of these patients are currently treated using pressurized metered dose inhalers (pMDIs) that can contribute to the global carbon footprint of respiratory care,” the statement from the companies reads.

They will, however, work together to bring various products to market. AstraZeneca completed a Phase I clinical trial, and the company expects its product Breztri Aerospehere to be the first to transition to the new platform once it has been cleared by regulators.

Following the completion of this Phase I trial, AstraZeneca will move forward with its commercial partnership with Honeywell to develop their triple-combination therapy, Breztri Aerosphere, with Honeywell’s near-zero GWP propellant technology.

The Report also shows that AstraZeneca’s imported electricity is now entirely renewable, and that the Company has reduced its Scope 1 and 2 greenhouse gas (GHG) emissions by 59 percent since 2015, including the integration of Alexion’s GHG footprint.

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “We are making great progress on our ambition to be zero carbon across our global operations by the end of 2025 and carbon negative across our entire value chain by 2030.

Our collaboration with Honeywell demonstrates AstraZeneca’s commitment to advancing sustainable healthcare innovation, with the aim of improving outcomes for patients while reducing our environmental footprint.”

AstraZeneca aims for 95 percent of its key suppliers and partners to have science-based targets by the end of 2025 to support its decarbonization goals.

Supply chain science-based climate targets

AstraZeneca is one of the first seven companies in the world to have their net zero targets validated by the Science Based Targets initiative (SBTi) in accordance with their Corporate Net Zero Standard.

The Company is dedicated to sharing the lessons learned from its own decarbonization journey, and is a founding member of the Energize program.

The Energize program was launched at COP26 and focuses on increasing access to renewable energy for pharmaceutical supply chains, as well as the Sustainable Markets Initiative (SMI) Health Systems Taskforce, which aims to accelerate the delivery of net zero healthcare.

Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE